The Causes & Treatments for Autism | Dr. Karen Parker
Huberman Lab Podcast Recap
Published:
Guests: Dr. Karen Parker, John Constantino
Summary
Dr. Karen Parker discusses the rising prevalence of autism, its heritable nature, and the potential treatments focusing on oxytocin and vasopressin. The episode highlights the complexity of autism and the need for early intervention and accurate biomarkers.
What Happened
Dr. Karen Parker, director of the Social Neurosciences research program at Stanford, addresses the increasing incidence of autism, now affecting 1 in 36 U.S. children. Autism is more prevalent in males and highly heritable, with its diagnosis based on social interaction challenges and repetitive behaviors. The episode discusses the polygenic nature of autism, with both genetic and environmental risk factors like advanced parental age and maternal illness during pregnancy.
The challenges in understanding autism include the difficulty of studying the human brain and the limitations of mouse models. Non-human primate models, specifically rhesus macaques, are now being used to better understand autism. These models help in measuring autistic-like traits through adapted social responsiveness scales. Low vasopressin levels in cerebrospinal fluid (CSF) have been identified as a biomarker for autism, correlating with social symptom severity.
Oxytocin and vasopressin, two chemically similar neurotransmitters, play significant roles in social behavior across species. Oxytocin has been explored as a treatment for autism, with mixed results. Initial studies showed potential benefits in improving social functioning, but a large phase three trial found no significant effects, partly due to challenges in measuring oxytocin levels accurately.
Vasopressin is emerging as a more promising treatment option than oxytocin for autism. Controlled trials show improvements in social abilities and reduced anxiety with vasopressin treatment. Vasopressin's role in social cognition and its potential as a treatment are still under investigation, with ongoing studies examining vasopressin levels in infants as a predictive marker for autism.
The episode also touches on the role of the gut microbiome in social functioning. Probiotics in mouse studies have shown the ability to normalize social functioning and increase levels of oxytocin and vasopressin in the hypothalamus. There are ongoing trials in humans with autism using fecal transplants to explore this avenue further.
Dr. Parker discusses the need for laboratory-based tests or biomarker panels to prioritize children for autism diagnosis and intervention. The long wait times for clinical diagnosis and treatment can delay early intervention, which is crucial for better outcomes. The potential for vasopressin replacement therapy to alter developmental trajectories in individuals with autism is being explored.
The podcast also debunks the myth of a link between vaccines and autism, a claim that was debunked and led to the discrediting of Andrew Wakefield. The discussion reiterates that multiple studies have shown no correlation between vaccines and autism, emphasizing the need to focus on scientifically backed research and interventions.
Dr. Parker emphasizes the importance of continued research and funding in the field of autism. Advocacy and philanthropy have increased focus on this historically underfunded area, with significant contributions from individuals like hedge fund manager Jim Simons. The urgency from parents for effective treatments drives ongoing research efforts.
Key Insights
- Autism is a highly heritable condition, with 40 to 80% of cases having a genetic basis. It is more prevalent in males, with a ratio of about three to four boys affected for every one girl.
- Oxytocin, although initially promising in treating autism, showed no significant benefits in a large phase three trial. The trial highlighted the technical challenges in measuring oxytocin levels accurately.
- Vasopressin has emerged as a more promising treatment option for autism, with trials showing improvements in social abilities and reduced anxiety. Low vasopressin levels in cerebrospinal fluid are a biomarker of autism, correlating with the severity of social symptoms.
- The gut microbiome plays a role in social functioning, with studies showing that probiotics can normalize social behavior and increase levels of oxytocin and vasopressin in the hypothalamus. Ongoing trials are exploring the use of fecal transplants in people with autism.